Evidence map›Paper›PMID 34069721›Full record

ReviewJournal of fungi (Basel, Switzerland)2021

Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value.

Allen Grace Niego, Sylvie Rapior, Naritsada Thongklang, Olivier Raspé, Wuttichai Jaidee, Saisamorn Lumyong, Kevin D Hyde

Abstract readReview
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed.

  1. Review
  2. Foods (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Preparation ofLife (Basel, Switzerland) · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Allen Grace NiegoCenter of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand.
Sylvie RapiorLaboratory of Botany, Phytochemistry and Mycology, Faculty of Pharmacy, CEFE, CNRS, University Montpellier, EPHE, IRD, CS 14491, 15 Avenue Charles Flahault, CEDEX 5, 34093 Montpellier, France.
Naritsada ThongklangCenter of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand.ORCID 0000-0001-9337-5001
Olivier RaspéCenter of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand.
Wuttichai JaideeMedicinal Plants Innovation Center, Mae Fah Luang University, Chiang Rai 57100, Thailand.
Saisamorn LumyongDepartment of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0002-6485-414X
Kevin D HydeCenter of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand.

Funding

Thailand Research Fund DBG6180015Thailand Science Research and Innovation DBG6280009
6 · The paper itself

Abstract

Macrofungi production and economic value have been increasing globally. The demand for macrofungi has expanded rapidly owing to their popularity among consumers, pleasant taste, and unique flavors. The presence of high quality proteins, polysaccharides, unsaturated fatty acids, minerals, triterpene sterols, and secondary metabolites makes macrofungi an important commodity. Macrofungi are well known for their ability to protect from or cure various health problems, such as immunodeficiency, cancer, inflammation, hypertension, hyperlipidemia, hypercholesterolemia, and obesity. Many studies have demonstrated their medicinal properties, supported by both in vivo and in vitro experimental studies, as well as clinical trials. Numerous bioactive compounds isolated from mushrooms, such as polysaccharides, proteins, fats, phenolic compounds, and vitamins, possess strong bioactivities. Consequently, they can be considered as an important source of nutraceuticals. Numerous edible mushrooms have been studied for their bioactivities, but only a few species have made it to the market. Many species remain to be explored. The converging trends and popularity of eastern herbal medicines, natural/organic food product preference, gut-healthy products, and positive outlook towards sports nutrition are supporting the growth in the medicinal mushroom market. The consumption of medicinal mushrooms as functional food or dietary supplement is expected to markedly increase in the future. The global medicinal mushroom market size is projected to increase by USD 13.88 billion from 2018 to 2022. The global market values of promising bioactive compounds, such as lentinan and lovastatin, are also expected to rise. With such a market growth, mushroom nutraceuticals hold to be very promising in the years to come.

Indexed as

bioactivitiesmacrofungimarket valuemedicinal propertiesnutraceuticalsnutrients

Identifiers

PMID34069721
PMCPMC8161071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.